Mutant BsteE Esterase Diastereoselective Hydrolysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for synthesizing biologically active molecules, particularly diastereoenriched difluoroalkylcyclopropyl and vinylalkylcyclopropyl esters, face challenges in achieving high levels of diastereoselectivity and are time-consuming and costly, often requiring complex processing steps.

Innovation Solution

The use of mutant enzymes, such as BsteE esterase variants with specific mutations like T25H and L92H, for diastereoselective enzymatic hydrolysis to directly produce diastereoenriched compounds, eliminating the need for racemate synthesis and diastereomer separation, and improving yield and selectivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional hydrolysis methods are used to synthesize difluoroalkylcyclopropyl esters, then the synthesis can be performed with standard reagents, but the diastereoselectivity is modest and requires additional separation steps

Engineering Contradiction:
ImprovediastereoselectivityVSAvoidprocess complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by modifying the enzyme's amino acid sequence (T25H and L92H mutations) to alter its catalytic properties. This changes the enzyme's selectivity parameters, enabling it to discriminate between diastereomers and achieve high diastereoselectivity (up to 98% de) in the hydrolysis reaction, resolving the contradiction between selectivity and process complexity

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent replaces mechanical/chemical separation methods with an enzymatic recognition system. The mutant enzyme inherently recognizes and selectively hydrolyzes one diastereomer through molecular recognition mechanisms, eliminating the need for post-reaction separation steps and reducing process complexity while maintaining high manufacturing precision

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If conventional synthesis methods are used, then standard chemical reagents and procedures can be employed, but the synthesis is time-consuming and requires isolation of diasterioenriched intermediates

Engineering Contradiction:
Improvesynthesis throughputVSAvoidsynthesis time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-engineering the enzyme with specific mutations (T25H, L92H) that confer high diastereoselectivity before the synthesis reaction. This preliminary modification of the catalyst ensures that the subsequent hydrolysis reaction proceeds directly to the desired diastereoenriched product without requiring time-consuming intermediate isolation steps, thereby increasing productivity and reducing synthesis time

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent extracts the separation step from the synthesis pathway by using the mutant enzyme's inherent selectivity. The enzyme selectively hydrolyzes the desired diastereomer in situ, effectively extracting the separation function from the overall process and allowing direct conversion to the final diastereoenriched product, thus improving throughput and reducing time loss

Inventive Principle:
Principle #2Taking out (Extraction)

3Manufacturing precision

If high levels of diastereoselectivity are achieved through conventional means, then diastereoenriched intermediates can be obtained, but the process becomes costly and complex

Engineering Contradiction:
Improvediastereomeric excessVSAvoidmanufacturing cost
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent applies universality by designing a single mutant enzyme that performs multiple functions: it acts as both the catalyst for hydrolysis and the selector for diastereomeric enrichment. The T25H/L92H mutant enzyme simultaneously achieves high catalytic activity and high diastereoselectivity (up to 98% de) in one step, eliminating the need for separate resolution steps and reducing manufacturing costs while maintaining high diastereomeric excess

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses the mutant enzyme as an intermediary that mediates between the starting material and the diastereoenriched product. The enzyme's mutated active site (with T25H and L92H substitutions) serves as a selective intermediary that recognizes and transforms only the desired diastereomer, achieving high manufacturing precision while simplifying the overall manufacturing process and reducing costs

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the efficiency and diastereoselectivity of the hydrolysis reaction, reducing processing steps and increasing throughput, while achieving high product yield and purity, as demonstrated by the production of (±)-2-(difluoromethyl)-1-(ethoxycarbonyl)cyclopropanecarboxylic acid with improved diastereomeric excess.

Implementation Method 1

diastereoselective enzymatic hydrolysis

Methodology Applied
Scientific EffectEnzymatic hydrolysis: Hydrolysis

Implementation Method 2

mutant enzymes, such as BsteE esterase variants with specific mutations like T25H and L92H, for diastereoselective enzymatic hydrolysis

Methodology Applied
Scientific EffectEnzyme catalysis: Catalysis

Data Source

PatentUS10689675B2Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
Publication Date: 2020.06.23 ABBVIE INC
  • US10689675B2 patent drawing
  • US10689675B2 patent drawing
  • US10689675B2 patent drawing

AI summary

Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt. Also disclosed are methods for preparing enantioenriched (1R,2R)-1-((tert-butoxycarbonyl)amino)-2-(difluoromethyl)cyclopropane-1-carboxylic acid and esters of the same. These compounds are useful intermediates in the synthesis of viral protease inhibitors.